GLIOMATCH successfully completes Reporting Period 1
GLIOMATCH has successfully completed its first reporting period (RP1), marking a key milestone in advancing data-driven precision medicine for malignant glioma. A new Results page is now available, providing access to public deliverables and scientific publications.